Darron Barrus
Foot & Ankle Surgery · Alabaster, ALNPI 1700967924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 76.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $197 and has fallen 78.4% since, to $43 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in AL, where the typical reported total is $4,589.
Across 36 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$587
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$121
- Smith+Nephew$28
- Stryker$19
- AbbVie$14
What the payments were for
- Speaking & faculty fees$608%
- Food & beverage$70892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 27 | $587 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $121 |
| Smith+Nephew | 2 | $28 |
| Stryker | 1 | $19 |
| AbbVie | 1 | $14 |
How this compares
$769 in reported general payments places this provider in the 15th percentile of 40 foot & ankle surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 50 | $1,836 |
| Ciclopirox | 40 | $1,445 |
| Doxycycline Hyclate | 25 | $257 |
| Cephalexin | 27 | $227 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $213 |
| Doxycycline Monohydrate | 12 | $123 |
| Methylprednisolone | 12 | $103 |
| Nabumetone | 16 | $95 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $69 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Alabaster
- Norman WaldropBirmingham$3.6M
- Justin DaigreDecatur$372K
- John KirchnerHoover$84K
- Jefferson SabatiniHuntsville$56K
- Matthew DeorioHuntsville$49K
- Patricia AnteroTuscaloosa$35K
- Ashish ShahBirmingham$28K
- Alfred RicciMontgomery$25K
- Swapnil SinghBirmingham$14K
- Derek KlavasMobile$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.